Achiko AG Announces Corporate Update Webcast

Commercial Delivery of its Saliva-Based Covid-19 Test AptameX^TM Has Commenced

REPLACES MEDIA RELEASE “ACHIKO AG ANNOUNCES CORPORATE UPDATE WEBCAST” FROM 16 NOVEMBER 2022, WHICH HAD BEEN ERRONEOUSLY SENT AS AD-HOC NEWS.

Zurich, 17 November 2022: Achiko AG (SIX: ACHI; OTCQB:  ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced today that it will hold a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 3.00pm CET/9.00am EST. A PowerPoint presentation will be available at the time of the call and published on the company website at https://www.achiko.com/financials.

Details of the webcast are as follows:
 

Date:                   22 November 2022
Time:                  3.00pm CET / 9.00am EST
Format:              Zoom Call
Presenter:          Mr Steven Goh, CEO of Achiko AG
Meeting link:     https://zoom.us/j/98404123755?pwd=Qk1jUytLVWFKb2JEcDZCNUt5MjdQdz09
Meeting ID:       984 0412 3755
Passcode:           achiko

Find your local number: https://us02web.zoom.us/u/knHHcenwR
 

Recently, Achiko announced that it is commencing commercial deliveries of its Generation 2 AptameX™ Covid-19 test kit to Nahdlatul Ulama and other commercial clients, both starting in and around Jakarta.  Nahdlatul Ulama is the Jakarta branch of Nahdlatul Ulama, which nationally in Indonesia has over 90 million registered members and operates over 6,000 schools and universities, and several hundred hospitals and clinics.

AptameX is the Company’s proprietary saliva-based Covid-19 test utilising DNA aptamers bound to gold nanoparticles in a colloidal solution.  The result is read by a UV Spectrophotometer and then analysed with custom software.  Unlike a molecular and immunoassay approaches, the test’s use of DNA aptamers has yielded encouraging results at low viral loads outperforming most lateral flow based rapid tests.
 

ABOUT ACHIKO AG 

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport.  AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022.  

The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.  

Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world. 
 

Media contacts:  

ACHIKO AG
Investor Relations
E: ir@achiko.com

Switzerland & Global
Marcus Balogh
Farner Consulting Ltd
E: achiko@farner.ch
T: +41 44 266 67 67
 

Disclaimer 
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise